Literature DB >> 2225668

Fractionated doses of radioiodine for ablation of postsurgical thyroid tissue remnants.

E Arad1, K Flannery, G A Wilson, R E O'Mara.   

Abstract

Patients who have differentiated thyroid carcinoma and have undergone total thyroidectomy are treated with radioiodine for ablation of functional thyroid remnants. Administration of a single therapeutic dose in excess of 30 mCi of l-131 requires hospitalization. In an attempt to obviate the necessity for hospitalization, the prospective ablative dose was divided into two or three fractions given at weekly intervals on an ambulatory basis. To assess the effectiveness of this approach, this group of patients was compared to a cohort of hospitalized patients treated with a single dose. Ablation was achieved in 9 out of 12 patients treated in a fractionated manner (a 75% success rate), whereas in 16 out of 20 patients given a single dose the thyroid remnants were completely eradicated (an 80% success rate). That the use of split, smaller doses administered at weekly intervals on an ambulatory basis presents a reasonable alternative for ablation of postsurgical, residual-functioning thyroid tissue.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225668

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

1.  Decreased uptake after fractionated ablative doses of iodine-131.

Authors:  Hurng-Sheng Wu; Huey-Herng Hseu; Wan-Yu Lin; Shyh-Jen Wang; Yao-Chi Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-04       Impact factor: 9.236

Review 2.  Radionuclide therapy of the thyroid.

Authors:  S E Clarke
Journal:  Eur J Nucl Med       Date:  1991

3.  The Effect of Diagnostic Absorbed Doses from 131I on Human Thyrocytes in Vitro.

Authors:  Zbigniew Adamczewski; Mariusz Stasiołek; Bolesław Karwowski; Marek Dedecjus; Daria Orszulak-Michalak; Anna Merecz; Przemysław W Śliwka; Bartosz Puła; Andrzej Lewiński
Journal:  Int J Mol Sci       Date:  2015-06-29       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.